o9 Solutions, a AI-powered IBP platform provider has announced that it would supply its next-generation platform to Samsung Bioepis bolstering the management of its biopharmaceutical product manufacturing and supply chain.
o9 Solutions’ platform will also help Samsung Bioepis optimise its focus on development, clinical trial management, and regulatory registration.
o9 Solutions’ unique platform, or ‘digital brain’, supports all planning phases, including long-term strategic planning to medium- and short-term execution. The platform will be integrated into the client’s existing enterprise resource planning (ERP), seamlessly providing efficiencies in supply chain management, financial management, and collaboration.
The integration of o9 Solutions’ digital brain into Samsung Bioepis will allow the company to leverage AI and analytics to streamline commercial planning, revenue planning, and gap closure activities. This conversion of data into knowledge will enable a better understanding of how best to drive initiatives from new products to marketing and pricing for incremental impact and an optimal mix of investment.
Chakri Gottemukkala, CEO, o9 Solutions, said, “Our SCM platform contract with Samsung Bioepis is o9 Solutions’ first project with a biopharmaceutical company, and we are very honored. We will be actively supporting Samsung Bioepis in its efforts to enhance productivity and reduce costs by providing our solutions to manage and plan pharmaceutical manufacturing and distribution.”